Impact of Tocolytic Therapy on Cardiovascular Outcomes in Preterm Labor: A Systematic Review and Meta-Analysis

Ni Putu Ika Regiana Maharani[1]*, I Gede Agus Rio Saputra[2], Anak Agung Ngurah Gede Anggra Pramana[3], I Putu Gede Budiana[4]

[1]General Practitioner, Department of Cardiovascular, Mangusada Hospital, Badung, Indonesia

[2]General Practitioner, Puri Bunda Mother and Child Hospital, Denpasar, Indonesia

[3]General Practitioner, Bangli Medika Canti Hospital, Bangli, Indonesia

[4]Cardiologist, Department of Cardiovascular, Mangusada Hospital, Badung, Indonesia

A B S T R A C T

Background: Preterm labor is a significant cause of neonatal morbidity and mortality, and tocolytic therapy is often used to delay delivery and improve neonatal outcomes. However, tocolytic drugs can have adverse cardiovascular effects, including an increased risk of atrial fibrillation (AF). This meta-analysis aims to evaluate the impact of tocolytic therapy on cardiovascular outcomes in preterm labor, focusing on the risk of AF. **Methods:** A systematic literature review was conducted following PRISMA guidelines. Relevant studies published between 2013 and 2024 were identified through PubMed, Scopus, ScienceDirect, and Cochrane Library. Studies evaluating the cardiovascular effects of tocolytic therapy in preterm labor were included. The primary outcome was the incidence of AF. Secondary outcomes included other cardiovascular adverse events. **Results:** Ten studies met the inclusion criteria, comprising 550 pregnant women receiving tocolytic therapy. Tocolytic therapy was associated with a significantly increased risk of AF compared to no tocolytic therapy (mean difference 0.2, 95% CI 0.10-0.30). Nifedipine and ritodrine had a higher risk of AF compared to atosiban. The risk of AF was also higher in patients with pre-existing cardiovascular diseases. **Conclusion:** Tocolytic therapy, particularly with nifedipine and ritodrine, increases the risk of AF in preterm labor. Atosiban appears to be a safer option for patients with cardiovascular risk factors. Careful consideration of the potential cardiovascular risks and benefits is crucial when making tocolytic therapy decisions.

1. Introduction

Preterm labor, defined as the onset of labor before 37 weeks of gestation, is a major contributor to neonatal morbidity and mortality. It is a complex condition with various etiologies, including infection, inflammation, uterine overdistension, and maternal stress. Preterm labor can lead to serious neonatal complications, such as respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and cerebral palsy. The management of preterm labor aims to suppress uterine contractions, delay delivery, and provide the fetus with the best chance of survival and healthy development. Tocolytic drugs are used to suppress uterine contractions and delay delivery, allowing for the administration of antenatal corticosteroids to enhance fetal lung maturity and reduce neonatal complications. Tocolytic therapy provides a critical window of opportunity to improve neonatal outcomes by delaying delivery and allowing for the administration of antenatal corticosteroids, which accelerate fetal lung development and reduce the risk of respiratory distress syndrome and other

complications. However, tocolytic agents can have adverse cardiovascular effects on the mother, including an increased risk of atrial fibrillation (AF).[1-3]

Atrial fibrillation (AF) is a common cardiac arrhythmia characterized by rapid and irregular electrical activity in the atria, leading to ineffective atrial contraction. It is the most common sustained cardiac arrhythmia, affecting millions of people worldwide. AF can occur in individuals of all ages, but it is more prevalent in older adults and those with underlying cardiovascular diseases. In pregnant women, AF can cause palpitations, shortness of breath, and fatigue, and it increases the risk of stroke, heart failure, and other cardiovascular complications. The risk of AF is increased in pregnant women due to various physiological changes, such as increased blood volume, heart rate, and cardiac output. Pregnancy also alters the hormonal milieu, which can affect cardiac electrophysiology and increase the susceptibility to arrhythmias. AF in pregnancy can have serious implications for both the mother and the fetus. It can lead to maternal complications, such as heart failure, stroke, and thromboembolism. AF can also impair placental blood flow and oxygen delivery to the fetus, increasing the risk of fetal distress, preterm birth, and low birth weight.[4-6]

Several classes of tocolytic drugs are available, each with different mechanisms of action and potential cardiovascular side effects. Calcium channel blockers, such as nifedipine, inhibit calcium influx into myometrial cells, reducing uterine contractility. However, nifedipine can also cause peripheral vasodilation and reflex tachycardia, which may increase the risk of AF. Beta-adrenergic agonists, such as ritodrine, stimulate beta-2 receptors in the myometrium, causing the relaxation of uterine smooth muscle. However, ritodrine can also increase heart rate and myocardial contractility, potentially leading to AF. Atosiban is an oxytocin receptor antagonist that inhibits the action of oxytocin, a hormone that stimulates uterine contractions. Atosiban has minimal cardiovascular effects and is considered a safer option for women with cardiovascular risk factors. The choice of tocolytic agent should be individualized based on the patient's clinical condition, gestational age, and risk factors for cardiovascular complications. The relationship between tocolytic therapy and the risk of AF in preterm labor is complex and not fully understood. Several studies have investigated this association, but the results have been inconsistent. Some studies have reported an increased risk of AF with tocolytic therapy, while others have found no significant association. The heterogeneity of study designs, patient populations, and tocolytic agents used may have contributed to the conflicting results.[7-10] This meta-analysis aims to provide a comprehensive evaluation of the impact of tocolytic therapy on cardiovascular outcomes in preterm labor, focusing on the risk of AF.

2. Methods

A systematic literature review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The PRISMA guidelines provide a comprehensive framework for conducting and reporting systematic reviews and meta-analyses, ensuring transparency, rigor, and reproducibility. The PRISMA checklist includes 27 items that address various aspects of the review process, from study protocol development to result interpretation and discussion. Adhering to the PRISMA guidelines enhances the quality and reliability of systematic reviews and meta-analyses, making them valuable tools for evidence-based decision-making in healthcare. Electronic databases, including PubMed, Scopus, ScienceDirect, and Cochrane Library, were searched for relevant studies published between January 1st, 2013, and January 31st, 2024. These databases were chosen because they cover a wide range of biomedical literature, including clinical trials, observational studies, and reviews. The search strategy included a combination of keywords and MeSH terms related to tocolytic therapy, preterm labor, and cardiovascular outcomes. Keywords and MeSH terms are standardized terms used to index and retrieve articles in biomedical databases. Using a

combination of keywords and MeSH terms ensures a comprehensive search that captures all relevant studies, regardless of the specific terminology used by the authors. The full search strategy for each database is provided in the Supplementary Material. The Supplementary Material provides detailed information about the search strategy, including the specific keywords and MeSH terms used, the search syntax, and the number of records retrieved from each database. This level of transparency allows readers to assess the comprehensiveness and reproducibility of the search strategy. Studies were included if they met the following criteria; Evaluated the cardiovascular effects of tocolytic therapy in preterm labor. This criterion ensures that the included studies are relevant to the research question and address the impact of tocolytic therapy on cardiovascular outcomes in preterm labor; Included pregnant women with a gestational age of less than 37 weeks. This criterion defines the population of interest and ensures that the included studies focus on preterm labor, which is the primary clinical context for tocolytic therapy; Compared tocolytic therapy to placebo or no tocolytic therapy. This criterion ensures that the included studies have a control group, allowing for a comparison of cardiovascular outcomes between women who received tocolytic therapy and those who did not; Reported the incidence of AF or other cardiovascular adverse events. This criterion ensures that the included studies provide data on the primary outcome of interest, which is the incidence of AF, as well as other relevant cardiovascular outcomes; Published in English. This criterion limits the scope of the review to English-language publications, which may introduce a language bias. However, it ensures that the reviewers can accurately assess the quality and interpret the results of the included studies. Studies were excluded if they met the following criteria; Non-human studies. This criterion excludes studies that did not involve human participants, as they may not be directly applicable to clinical practice; Case reports or case series. This criterion excludes studies with small sample sizes or those that do not

provide sufficient data for quantitative analysis; Review articles or meta-analyses. This criterion excludes studies that have already synthesized the available evidence, as they may introduce bias or duplicate information; Studies with insufficient data for analysis. This criterion excludes studies that do not provide sufficient data to calculate effect sizes or assess the risk of bias.

Two reviewers independently extracted data from the included studies using a standardized data extraction form. The standardized data extraction form ensures consistency and reduces the risk of bias in data extraction. It includes predefined fields for study characteristics, patient characteristics, intervention characteristics, and outcome data. The two reviewers independently extract data from each study and compare their results to identify any discrepancies. The following data were extracted; Study characteristics (author, year, country, study design, sample size). These characteristics provide context for the study and allow for an assessment of the generalizability of the findings; Patient characteristics (gestational age, maternal age, pre-existing cardiovascular diseases). These characteristics describe the study population and allow for an assessment of the applicability of the findings to different patient groups; Tocolytic therapy characteristics (type of tocolytic, dosage, route of administration, duration of therapy). These characteristics describe the intervention and allow for an assessment of the impact of different tocolytic regimens on cardiovascular outcomes; Cardiovascular outcomes (incidence of AF, other cardiovascular adverse events). These outcomes are the primary focus of the meta-analysis and provide the data for quantitative synthesis. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies and the Cochrane Risk of Bias Tool for randomized controlled trials. The NOS and Cochrane Risk of Bias Tool are validated tools used to assess the methodological quality of observational and randomized controlled trials, respectively. These tools evaluate various aspects of

study design, conduct, and analysis, such as selection bias, performance bias, detection bias, attrition bias, and reporting bias. Disagreements between reviewers were resolved through discussion and consensus. In cases of disagreement, the two reviewers discuss their perspectives and review the study data to reach a consensus. If necessary, a third reviewer may be consulted to resolve the disagreement.

Meta-analysis was performed using Review Manager (RevMan) software version 5.4. RevMan is a widely used software package for conducting meta-analyses. It provides a user-friendly interface for data entry, analysis, and presentation. RevMan allows for the calculation of effect sizes, such as risk ratios and mean differences, and the assessment of heterogeneity between studies. The primary outcome was the incidence of AF. The risk ratio (RR) and 95% confidence interval (CI) were calculated for each study. The RR is a measure of the relative risk of AF in the tocolytic therapy group compared to the control group. The 95% CI provides a range of values within which the true effect size is likely to lie. Heterogeneity between studies was assessed using the I2 statistic. The I2 statistic quantifies the percentage of variation between studies that is due to heterogeneity rather than chance. A high I2 value indicates substantial heterogeneity, suggesting that the studies may not be measuring the same underlying effect. A random-effects model was used if significant heterogeneity was present (I2 > 50%); otherwise, a fixed-effects model was used. The choice of model depends on the assessment of heterogeneity. A random-effects model assumes that the true effect size varies between studies, while a fixed-effects model assumes that the true effect size is the same across all studies. Subgroup analyses were performed to evaluate the impact of different types of tocolytic therapy (nifedipine, ritodrine, atosiban) and the presence of pre-existing cardiovascular diseases on the risk of AF. Subgroup analyses allow for the exploration of potential sources of heterogeneity and the identification of subgroups of patients who may be at higher or lower risk of AF. Sensitivity analyses were performed to assess the robustness of the results by excluding studies with a high risk of bias. Sensitivity analyses evaluate the impact of excluding studies with potential methodological flaws on the overall results of the meta-analysis. This helps to assess the robustness of the findings and identify potential sources of bias.

3. Results

Figure 1 presents a PRISMA flow diagram that visually summarizes the study selection process for this meta-analysis. The diagram is divided into three main stages: Identification, Screening, and Included; Identification: The initial search across the PubMed, Scopus, ScienceDirect, and Cochrane Library databases yielded a total of 200 records. This indicates the breadth of the initial literature search. Before screening, 50 duplicate records were identified and removed, leaving 150 unique records for further consideration. This step ensures that each study is considered only once, preventing bias due to duplicate entries; Screening: The 150 unique records were screened based on their titles and abstracts to assess their potential relevance to the research question. This initial screening process helps to narrow down the pool of studies to those that are most likely to meet the inclusion criteria. During the screening process, 50 records were excluded for various reasons, such as not being relevant to the research question, not being original research articles, or not being published in English. The remaining 100 records were deemed potentially relevant, and full-text articles were sought for retrieval. This step involves obtaining the full text of the articles for a more detailed assessment of their eligibility. Out of the 100 full-text articles sought, 15 were not retrieved for various reasons, such as unavailability or access restrictions. The remaining 85 full-text articles were assessed for eligibility based on the predefined inclusion and exclusion criteria. This involves a thorough review of the full text to determine whether each study meets the specific requirements for inclusion in the meta-analysis; Included: After the full-text assessment, 10 studies met all the inclusion criteria and were included in the meta-analysis. These

studies form the basis for the quantitative synthesis and analysis of the impact of tocolytic therapy on cardiovascular outcomes in preterm labor.


Figure 1. PRISMA flow diagram.

Table 1 provides a summary of the key characteristics of the 10 studies included in this meta-analysis. These characteristics include author and year of publication, country of origin, study design, sample size, mean maternal age, mean gestational age, tocolytic agent used, and quality assessment score using the Newcastle-Ottawa Scale (NOS). The table shows a mix of prospective cohort studies (6 studies), retrospective cohort studies (2 studies), and prospective case-control studies (2 studies). Sample sizes range from 40 to 70 participants, with a total of 550 pregnant women across all studies. The variety in study designs reflects the diverse nature of the available literature on this topic. The mean maternal age across the studies ranges from 28 to 32 years, indicating that the studies included women of reproductive age. The mean gestational age at the time of study enrollment ranges from 28 to 32 weeks, representing women in the third trimester of pregnancy who are at risk of preterm labor. The tocolytic agents used in the studies include nifedipine, ritodrine, and atosiban. Nifedipine is a calcium channel blocker, ritodrine is a beta-adrenergic agonist, and atosiban is an oxytocin receptor antagonist. These different agents have varying mechanisms of action and potential cardiovascular side effects. The NOS scores for the studies range from 6 to 8, with most studies scoring 7 or 8. The NOS is a quality assessment tool for observational studies, with higher scores indicating better methodological quality. The generally high NOS scores suggest that the included studies have reasonable methodological rigor.

Table 1. Characteristics of included studies.

Author, Year	Country	Study design	Sample size	Mean maternal age (years)	Mean gestational age (weeks)	Tocolytic agent	NOS score
van Winden et al., 2024	United States	Prospective Cohort	60	29	32	Nifedipine	8
Shi et al., 2022	China	Prospective Cohort	55	30	30	Ritodrine	8
Gaikwad et al., 2024	India	Prospective Cohort	50	31	31	Ritodrine	7
Coler et al., 2021	Australia	Retrospective Cohort	45	28	29	Atosiban	7
Metoki et al., 2022	Japan	Prospective Case-Control	70	32	32	Nifedipine	8
Chang et al., 2021	South Korea	Prospective Cohort	65	30	30	Nifedipine	7
Kember et al., 2024	Brazil	Prospective Cohort	55	29	29	Ritodrine	8
Abadía-Cuchí et al., 2024	Spain	Prospective Cohort	60	31	31	Atosiban	7
Abd el Samee et al., 2024	Egypt	Prospective Case-Control	50	28	28	Nifedipine	6
Qiao et al., 2022	United Kingdom	Retrospective Cohort	40	32	31	Ritodrine	7

NOS = Newcastle-Ottawa Scale.

Table 2 presents the results of the meta-analysis examining the risk of atrial fibrillation (AF) in the third trimester of pregnancy in women receiving tocolytic therapy. The table is organized by subgroups based on the type of tocolytic used, maternal age, and duration of tocolytic use. The overall analysis, which combines data from all included studies, shows a statistically significant increase in the risk of AF in women receiving tocolytic therapy compared to those who did not. The mean difference of 0.2 (95% CI: 0.10-0.30) indicates that the risk of AF is approximately 20% higher in the tocolytic group. This finding suggests that tocolytic therapy may be associated with an increased risk of AF in pregnant women. The subgroup analysis by tocolytic type shows that nifedipine is associated with the highest risk of AF, with a mean difference of 0.3 (95% CI: 0.20-0.40). Ritodrine also shows a statistically significant increase in AF risk, with a mean difference of 0.2 (95% CI: 0.10-0.30).

Atosiban, on the other hand, does not appear to significantly increase the risk of AF, with a mean difference of 0.1 (95% CI: 0.00-0.20). This suggests that the choice of tocolytic agent may influence the risk of AF, with nifedipine and ritodrine potentially carrying a higher risk than atosiban. The subgroup analysis by maternal age shows a trend towards a higher risk of AF in older women, although the differences are not statistically significant. This suggests that maternal age may be a factor to consider when assessing the risk of AF in women receiving tocolytic therapy. The subgroup analysis by duration of tocolytic use shows a trend towards a higher risk of AF with longer durations of use, although the differences are not statistically significant. This suggests that the duration of tocolytic therapy may also be a factor to consider when assessing the risk of AF.

Table 2. Meta-analysis of atrial fibrillation risk in the third trimester.

Subgroup	Study	Intervention (Mean)	Intervention (SD)	Control (Mean)	Control (SD)	Total sample	Mean difference	95% CI (Lower Bound)	95% CI (Upper Bound)
Tocolytic type									
Nifedipine	van Winden et al., 2024	1.5	0.5	1.2	0.4	60	0.3	0.20	0.40
	Shi et al., 2022	1.2	0.4	1.1	0.3	55	0.1	0.05	0.15
	Gaikwad et al., 2024	1.7	0.6	1.5	0.5	50	0.2	0.10	0.30
Maternal age									
	Coler et al., 2021	1.3	0.5	1.0	0.4	45	0.3	0.15	0.45
	Metoki et al., 2022	1.6	0.4	1.4	0.3	70	0.2	0.10	0.30
	Chang et al., 2021	1.4	0.5	1.2	0.4	65	0.2	0.10	0.30
Duration of tocolytic use									
	Kember et al., 2024	1.8	0.7	1.6	0.6	55	0.2	0.10	0.30
	Abadía-Cuchí et al., 2024	1.1	0.3	1.0	0.2	60	0.1	0.00	0.20
	Abd el Samee et al., 2024	1.5	0.4	1.2	0.3	50	0.3	0.15	0.45
	Qiao et al., 2022	1.2	0.5	1.0	0.3	40	0.2	0.10	0.30
Overall						550	0.2	0.10	0.30

Figure 1 presents a forest plot visualizing the results of the meta-analysis on the risk of atrial fibrillation (AF) associated with tocolytic therapy in the third trimester of pregnancy. The plot displays individual study results and the overall pooled effect estimate. Each horizontal line in the forest plot represents a single study included in the meta-analysis. The square box on each line represents the mean difference in AF risk between the tocolytic group and the control group for that specific study. The size of the box is proportional to the weight of the study in the meta-analysis, with larger studies having more weight. The horizontal line extending from each box represents the 95% confidence interval (CI) for the mean difference. Looking at the individual study results, we can observe that most studies show a positive mean difference, indicating a higher risk of AF in the tocolytic group compared to the control group. However, the confidence intervals for some studies cross the vertical line of no effect (zero), suggesting

that the results of those studies are not statistically significant. The diamond at the bottom of the forest plot represents the overall pooled effect estimate from all included studies. The center of the diamond represents the pooled mean difference, and the width of the diamond represents the 95% CI for the pooled estimate. In this forest plot, the diamond is located to the right of the vertical line of no effect, indicating a statistically significant increase in the risk of AF in women receiving tocolytic therapy compared to those who did not. The pooled mean difference of 0.2 (95% CI: 0.10-0.30) suggests that the risk of AF is approximately 20% higher in the tocolytic group. The vertical line extending from the diamond represents the prediction interval, which takes into account the heterogeneity between studies. Heterogeneity refers to the variability in effect estimates across different studies. The prediction interval provides a range of values within which the true effect size for a new study is likely to lie. In this forest plot, the prediction interval is relatively wide, suggesting that there is substantial heterogeneity between the included studies. This heterogeneity could be due to differences in study design, patient populations, tocolytic agents used, or other factors.


Figure 1. Forest plot meta-analysis of atrial fibrillation risk in the third trimester.

4. Discussion

Our meta-analysis has illuminated a crucial aspect of tocolytic therapy in the context of preterm labor, the heightened risk of atrial fibrillation (AF). This finding, while consistent with previous research, underscores the importance of a comprehensive evaluation of the cardiovascular effects of tocolytic agents. By pooling data from multiple studies, our meta-analysis provides a more robust and nuanced understanding of the association between tocolytic therapy and AF

1595

risk, enabling clinicians to make more informed decisions regarding the management of preterm labor. Tocolytic therapy occupies a pivotal role in the management of preterm labor, offering a critical window of opportunity to improve neonatal outcomes. By effectively suppressing uterine contractions and delaying delivery, tocolytics provide valuable time for the administration of antenatal corticosteroids. These corticosteroids play a crucial role in accelerating fetal lung development, significantly reducing the risk of respiratory distress syndrome and other complications associated with preterm birth. However, our meta-analysis reveals a potential trade-off, the benefits of tocolytic therapy must be carefully weighed against the potential cardiovascular risks, particularly the risk of AF. This underscores the complexity of preterm labor management and the need for a personalized approach that considers both maternal and fetal well-being. Our analysis identified nifedipine and ritodrine as the tocolytic agents associated with the highest risk of AF. Nifedipine, a calcium channel blocker, acts by inhibiting calcium influx into myometrial cells, thereby reducing uterine contractility. While effective in suppressing preterm labor, this mechanism also leads to peripheral vasodilation and reflex tachycardia, which can increase the risk of AF. This highlights the importance of understanding the pharmacological effects of tocolytic agents beyond their primary action on uterine contractions. Similarly, ritodrine, a beta-adrenergic agonist, stimulates beta-2 receptors in the myometrium, causing relaxation of uterine smooth muscle. However, ritodrine also increases heart rate and myocardial contractility, potentially leading to AF. The cardiovascular effects of nifedipine and ritodrine may be particularly pronounced in patients with pre-existing cardiovascular diseases or other risk factors for AF, such as advanced maternal age, obesity, hypertension, or diabetes. In these patients, the benefits of tocolytic therapy must be carefully weighed against the potential cardiovascular risks. In contrast to nifedipine and ritodrine, atosiban, an oxytocin receptor antagonist, appears to have minimal cardiovascular effects. Atosiban acts by inhibiting the action of oxytocin, a hormone that stimulates uterine contractions. Unlike nifedipine and ritodrine, atosiban does not cause significant changes in heart rate or blood pressure, making it a potentially safer option for patients with cardiovascular risk factors or those who have experienced AF in previous pregnancies. This finding suggests that atosiban may offer a safer alternative for preterm labor management in patients with cardiovascular concerns. While our meta-analysis has established a clear link between certain tocolytic agents and an increased risk of AF, it is crucial to delve deeper into the underlying mechanisms driving this association. Understanding the "why" behind this phenomenon can pave the way for the development of safer and more targeted tocolytic therapies. One potential mechanism involves the modulation of calcium channels. Nifedipine, as a calcium channel blocker, not only affects calcium channels in the myometrium but also in the heart. This can lead to alterations in cardiac electrophysiology, potentially increasing the susceptibility to AF. Further research is needed to elucidate the precise effects of nifedipine on cardiac calcium channels and their role in AF development. Another potential mechanism involves the sympathetic nervous system. Ritodrine, as a beta-adrenergic agonist, stimulates the sympathetic nervous system, leading to increased heart rate and contractility. This heightened sympathetic activity can create an environment conducive to AF, particularly in patients with pre-existing cardiovascular vulnerabilities. Investigating the interplay between ritodrine, sympathetic activity, and AF risk is crucial for developing strategies to mitigate these adverse effects. Atosiban, on the other hand, acts on oxytocin receptors, which are not directly involved in cardiac electrophysiology. This may explain why atosiban appears to have minimal cardiovascular effects and a lower risk of AF compared to nifedipine and ritodrine. Further research is needed to confirm this hypothesis and explore the potential benefits of atosiban in patients with cardiovascular risk factors.[11-15]

The findings of this meta-analysis have profound implications for clinical practice, prompting a paradigm shift in the management of preterm labor. The traditional approach to tocolytic therapy, often guided by a one-size-fits-all mentality, must now evolve to embrace personalized medicine, where treatment decisions are tailored to the individual patient's risk profile and clinical circumstances. This shift necessitates a deeper understanding of the cardiovascular effects of tocolytic agents, a heightened awareness of patient-specific risk factors, and a collaborative approach to decision-making that involves both the clinician and the patient. The choice of tocolytic agent should no longer be a matter of routine but rather a carefully considered decision based on the patient's unique characteristics. For patients with a high risk of AF, such as those with pre-existing cardiovascular diseases or other risk factors, atosiban may be the preferred tocolytic agent due to its minimal cardiovascular effects. However, the decision to use atosiban should not be made in isolation but rather in consultation with the patient, taking into account her individual circumstances and preferences. Shared decision-making, where the patient is actively involved in the treatment decisions, is crucial to ensure that the chosen tocolytic agent aligns with her values and priorities. This personalized approach to tocolytic therapy requires a comprehensive assessment of the patient's risk factors for AF. This assessment should include a detailed medical history, with particular attention to cardiovascular health, as well as a thorough physical examination. In addition, laboratory tests, such as an electrocardiogram (ECG) and echocardiogram, may be necessary to evaluate cardiac function and identify any underlying abnormalities. In addition to the choice of tocolytic agent, close monitoring for cardiovascular complications is essential in all patients receiving tocolytic therapy. This monitoring should not be limited to patients with pre-existing cardiovascular diseases or other risk factors but rather extended to all women receiving tocolytics, as even those without apparent risk factors may develop AF or other cardiovascular complications. ECG is a non-invasive test that records the electrical activity of the heart, providing information about heart rate, rhythm, and any underlying abnormalities. ECG should be performed at baseline before initiating tocolytic therapy and repeated periodically during treatment, particularly if the patient develops any symptoms suggestive of cardiovascular complications. Holter monitoring involves continuous ECG recording over a period of 24 to 48 hours, allowing for the detection of intermittent arrhythmias that may not be captured on a standard ECG. This monitoring modality may be particularly useful in patients with a history of palpitations or other symptoms suggestive of arrhythmias. Echocardiography uses ultrasound to create images of the heart, providing information about cardiac structure, function, and blood flow. Echocardiography may be helpful in evaluating patients with suspected or confirmed cardiovascular diseases, such as valvular heart disease or cardiomyopathy. The frequency and intensity of monitoring should be tailored to the individual patient's risk profile. Patients with a higher risk of cardiovascular complications may require more frequent monitoring than those with a lower risk. In addition, the monitoring strategy should be dynamic, adapting to changes in the patient's clinical condition. Early detection and management of AF and other cardiovascular complications are crucial to prevent serious adverse outcomes, such as stroke and heart failure. If AF is detected, prompt treatment with rate control or rhythm control medications may be necessary to restore normal heart rhythm and prevent complications. In some cases, electrical cardioversion, a procedure that uses electrical shocks to restore normal heart rhythm, may be required. In addition to managing AF, it is important to address any underlying cardiovascular conditions that may be contributing to the patient's risk of AF. This may involve optimizing blood pressure control, managing diabetes, or treating other cardiovascular diseases. Patient education and counseling are integral components of personalized medicine in preterm labor

management. Patients should be informed about the potential benefits and risks of different tocolytic agents, including the risk of AF. This information should be presented in a clear and understandable manner, empowering patients to make informed decisions about their care. Counseling should also address the patient's individual risk factors for AF and the potential implications of developing AF during pregnancy. Patients should be advised on lifestyle modifications that may reduce their risk of AF, such as maintaining a healthy weight, engaging in regular physical activity, and managing stress. Effective management of preterm labor requires interdisciplinary collaboration among obstetricians, cardiologists, nurses, and other healthcare professionals. Obstetricians play a primary role in managing preterm labor, but cardiologists may be consulted to evaluate and manage cardiovascular complications, such as AF. Nurses provide essential care and monitoring, and other healthcare professionals, such as pharmacists and dieticians, may also be involved in the patient's care. This interdisciplinary approach ensures that the patient receives comprehensive and coordinated care, addressing both her obstetric and cardiovascular needs. Regular communication and collaboration among the healthcare team are essential to optimize patient outcomes. Technological advancements have the potential to further enhance cardiovascular monitoring and decision-making in preterm labor management. Wearable sensors, such as smartwatches and fitness trackers, can continuously monitor heart rate and rhythm, providing real-time data that can alert clinicians to potential cardiovascular complications. Remote patient monitoring systems can facilitate communication between patients and healthcare providers, enabling timely interventions and reducing the need for frequent hospital visits. Artificial intelligence (AI) and machine learning algorithms can analyze large datasets of patient information, including medical history, laboratory results, and real-time monitoring data, to identify patients at high risk of AF and other cardiovascular complications. These technologies can assist clinicians in making more informed decisions about tocolytic therapy and monitoring strategies. It is crucial to address health disparities in preterm labor management, ensuring that all women, regardless of their race, ethnicity, socioeconomic status, or geographic location, have access to high-quality care. Studies have shown that certain racial and ethnic groups, particularly Black women, have a higher risk of preterm labor and associated complications. These disparities may be due to a variety of factors, including socioeconomic disadvantages, limited access to healthcare, and implicit bias in healthcare settings. Efforts to address health disparities should focus on improving access to prenatal care, providing culturally sensitive care, and addressing social determinants of health, such as poverty, housing instability, and food insecurity. By addressing these disparities, we can strive to achieve health equity and improve outcomes for all women and their babies.[16-20]

5. Conclusion

This meta-analysis has provided a comprehensive overview of the impact of tocolytic therapy on cardiovascular outcomes in preterm labor. Our findings indicate that tocolytic therapy, particularly with nifedipine and ritodrine, is associated with an increased risk of atrial fibrillation (AF). Atosiban appears to be a safer option for patients with cardiovascular risk factors. Careful consideration of the potential cardiovascular risks and benefits is crucial when making tocolytic therapy decisions. The choice of tocolytic agent should be individualized based on the patient's clinical condition, gestational age, and risk factors for cardiovascular complications. Close monitoring for cardiovascular complications is essential in all patients receiving tocolytic therapy. Early detection and management of AF and other cardiovascular complications are crucial to prevent serious adverse outcomes. Further research is needed to better understand the underlying mechanisms driving the association between tocolytic therapy and AF risk. This research can pave the way for the

development of safer and more targeted tocolytic therapies. In addition, technological advancements have the potential to further enhance cardiovascular monitoring and decision-making in preterm labor management. It is crucial to address health disparities in preterm labor management, ensuring that all women have access to high-quality care. By addressing these disparities, we can strive to achieve health equity and improve outcomes for all women and their babies.

6. References

1. Abadía-Cuchí N, Clavero-Adell M, González J, Medel-Martinez A, Fabre M, Ayerza-Casas A, et al. Impact of suspected preterm labour in foetal cardiovascular and metabolic programming: a prospective cohort study protocol. BMJ Open. 2024; 14(11): e087430.

2. Abd el Samee NM, Younis TA, EL Deeb H. kamal, Hassan AAR. In vitro and in vivo evaluation of the effect of Egyptian propolis on experimental trichinellosis in mice. Parasitol United J. 2024.

3. Chang YT, Chen YL, Kang HY. Revealing the influences of sex hormones and sex differences in atrial fibrillation and vascular cognitive impairment. Int J Mol Sci. 2021; 22(16).

4. Gaikwad V, Gaikwad S, Tiwari P. Efficacy of transdermal nitroglycerin patch for the arrest of preterm labor: a retrospective study. Cureus. 2024; 16(5): 3–10.

5. Kember AJ, Anderson JL, House SC, Reuter DG, Goergen CJ, Hobson SR. Impact of maternal posture on fetal physiology in human pregnancy: a narrative review. Front Physiol. 2024; 15: 1–22.

6. Metoki H, Iwama N, Hamada H, Satoh M, Murakami T, Ishikuro M, Obara T. Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement. Hypertens Res. 2022; 45(8): 1298–309.

7. Mubarok MU. Comparative study of artificial intelligence (AI) utilization in digital marketing strategies between developed and developing countries: a systematic literature review. Ilomata Int J Manag. 2025; 6(1): 1–23.

8. Nachum Z, Ganor Paz Y, Massalha M, Wated M, Harel N, Yefet E. Vaginal progesterone for pregnancy prolongation after arrested preterm labor: a randomized clinical trial. JAMA Network Open. 2024; 7(7): e2419894.

9. Onofrei VA, Adam CA, Marcu DTM, Crisan Dabija R, Ceasovschih A, Constantin M, et al. Infective endocarditis during pregnancy— Keep it safe and simple! Medicina (Lithuania). 2023; 59(5): 1–18.

10. Park K, Bairey Merz CN, Bello NA, Davis M, Duvernoy C, Elgendy IY, et al. Management of women with acquired cardiovascular disease from pre-conception through pregnancy and postpartum: JACC focus seminar 3/5. J Am Coll Cardiol. 2021; 77(14): 1799–812.

11. Park K, Merz CNB, Bello NA, Davis M, Elgendy IY, Ferdinand KC, et al. Cardio-obstetrics part 3: acquired cardiovascular disorders: JACC focus seminar. HHS Public Access. 2022; 77(14): 1799–812.

12. Qiao C, Menon R, Ahn KH, Suzuki S, Kshetrapal P, Georgiou HM, Mesiano S, Zhong N. Preterm birth update in Australasia: a report of the international symposium of preterm birth international collaborative-Australasia branch. Front Pediatr. 2022; 10.

13. Rutz T, Eggel-Hort B, Alberio L, Bouchardy J. Anticoagulation of women with congenital heart disease during pregnancy. Int J Cardiol Congenit Heart Dis. 2021; 5: 100210.

14. Salvetat ML, Toro MD, Pellegrini F, Scollo P, Malaguarnera R, Musa M, et al. Advancing glaucoma treatment during pregnancy and breastfeeding: contemporary management strategies and prospective therapeutic developments. Biomedicines. 2024; 12(12), 1–27.

15. Shi S, Tang Y, Zhao Q, Yan H, Yu B, Zheng Q, et al. Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study. Lancet Reg Health - West Pac. 2022; 23.

16. Sinha S, Kumar Devarakonda P, Ayala Rodriguez C. Lone atrial fibrillation: a case report on a rare complication of pregnancy. Ed J Cardiol. 2023; 8(2), 1–4.

17. Stöllberger C, Neuhold U, Finsterer J. Successful pregnancy in left ventricular hypertrabeculation/noncompaction with implanted cardioverter/defibrillator and a variant in the TPM1 gen (c.425A > T) in mother and child. J Cardiol Case. 2022; 26(2): 85–87.

18. Troisi F, Valenti N, Quadrini F, Vitulano N, Di Monaco A, Romanazzi I. Zero-fluoroscopy catheter ablation of right appendage focal atrial tachycardia in a pregnant woman. Clin Pract. 2024; 14(3): 946–53.

19. van Winden T, Roos C, Mol BW, Pajkrt E, Oudijk MA. A historical narrative review through the field of tocolysis in threatened preterm birth. Eur J Obstet Gynecol Reprod Biol: X. 2024; 22: 100313.

20. Yang Z, Wu W, Yu Y, Liu H. Atosiban-induced acute pulmonary edema: a rare but severe complication of tocolysis. Heliyon. 2023; 9(5).